Bionano Genomics's total inventories for the quarter that ended in Mar. 2026 was $5.31 Mil. Bionano Genomics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $5.38 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Bionano Genomics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $N/A.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Bionano Genomics's Days Inventory for the
three
months ended in Mar. 2026 was 142.85.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bionano Genomics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.64.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bionano Genomics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.80.
Bionano Genomics (NAS:BNGOW) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Bionano Genomics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bionano Genomics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Bionano Genomics Total Inventories Related Terms
Bionano Genomics Total Inventories Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Bionano Genomics (BNGOW) has a Total Inventories of $5.31 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Bionano Genomics and its competitors.
Is Bionano Genomics' Total Inventories too high?
Bionano Genomics' current Total Inventories is $5.31 Mil. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Total Inventories compare to UEEC and ZJYL?
Bionano Genomics' Total Inventories of $5.31 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Bionano Genomics and its competitors. Bionano Genomics's current Total Inventories is $5.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current Total Inventories of $5.31 Mil. The current Total Inventories is $5.31 Mil. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current Total Inventories is $5.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for BNGOW
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
